Ipamorelin
Also known as: NNC 26-0161
Selective ghrelin mimetic that triggers rapid growth hormone release without affecting cortisol or prolactin.
Evidence
Moderate
FDA status
Not FDA-approved
Source
Synthetic ghrelin mimetic pentapeptide
Overview
Selective ghrelin mimetic that triggers rapid growth hormone release without affecting cortisol or prolactin.
Mechanism of Action
Binds ghrelin receptor (GHS-R1a) on pituitary cells, triggers rapid GH release without hypothalamic involvement, no cortisol or prolactin elevation, studied alongside GHRH analogs.
What research has looked at
Effects reported in studies, not proven benefits. See the evidence section below for how strong the research is.
- Rapid GH pulse induction
- No cortisol or prolactin spike
- Improved body composition
- Enhanced recovery
- Better sleep
- Combination with GHRH analogs (research)
Researched for
Research topics, not approved uses.
How Gabriel approaches peptides
Through Gabriel, licensed clinicians may prescribe BPC-157, TB-500, MOTS-c, epitalon and semax (nasal) as compounded medications from licensed 503A pharmacies, under HHS's October 28, 2026 interim policy, and only when appropriate. They are not FDA-approved, and Gabriel never gives peptide dosing. Ipamorelin isn't prescribed through Gabriel. If you're thinking about it, Gabriel can help you find a licensed clinician to look at the cause of what you're dealing with and the options with stronger evidence.
Research & Evidence
Clinical trials, safety studies in adults
Human studies show it raises GH. It was tested for bowel recovery after surgery and development stopped. FDA lists it among bulk substances that may present significant safety risks in compounding.
Safety Information
Potential Side Effects
- •Increased hunger
- •Water retention (mild)
- •Headache
Contraindications
- Active cancer
- Pregnancy
- Breastfeeding
Interactions
- ⚠Synergistic with GHRH analogs
Quick Facts
Related Peptides
CJC-1295
Long-acting GHRH analog that stimulates sustained growth hormone release.
Tesamorelin
Synthetic GHRH analog FDA-approved for reducing visceral adipose tissue in HIV-associated lipodystrophy.
Sermorelin
Short-acting GHRH analog that stimulates natural pulsatile growth hormone release from the pituitary.